LRP5 and breast cancer: Lrp5-overexpressing osteocyte-derived conditioned medium (CM) also inhibited EdU-based proliferation and scratch-based migration of MDA-MB-231 breast cancer cells and EO771 mammary tumor cells (Figure S6).